82 related articles for article (PubMed ID: 3564858)
1. Bone marrow histology in multiple myeloma: autopsy studies on treated and untreated patients.
Hashimoto N
Nihon Ketsueki Gakkai Zasshi; 1986 Dec; 49(8):1774-83. PubMed ID: 3564858
[No Abstract] [Full Text] [Related]
2. Bone marrow changes following chemotherapy for multiple myeloma--a clinicopathological study of biopsy cases.
Kurihara K; Hill W; Burkhardt R; Kettner G; Hashimoto N
Nihon Ketsueki Gakkai Zasshi; 1987 Jul; 50(4):876-89. PubMed ID: 3687331
[No Abstract] [Full Text] [Related]
3. [Therapeutic application of sequential bone marrow biopsy in myeloma: analysis of 13 medullary biopsies].
Paule B; Médicis P; Clerc D; Bennet P; Bisson M; Massias P
Biomed Pharmacother; 1986; 40(7):261-4. PubMed ID: 3814757
[TBL] [Abstract][Full Text] [Related]
4. Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents.
Moulopoulos LA; Dimopoulos MA; Christoulas D; Kastritis E; Anagnostou D; Koureas A; Roussou M; Gavriatopoulou M; Migkou M; Iakovaki M; Gkotzamanidou M; Tasidou A; Terpos E
Leukemia; 2010 Jun; 24(6):1206-12. PubMed ID: 20428203
[No Abstract] [Full Text] [Related]
5. [Role of thalidomide in the treatment of multiple myeloma].
Mikala G; Jákó J; Vályi-Nagy I
Orv Hetil; 2001 Aug; 142(33):1789-98. PubMed ID: 11573449
[TBL] [Abstract][Full Text] [Related]
6. Histomorphology of multiple myeloma on bone marrow biopsy.
Singhal N; Singh T; Singh ZN; Shome DK; Gaiha M
Indian J Pathol Microbiol; 2004 Jul; 47(3):359-63. PubMed ID: 16295424
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer and acute leukemia in a patient with multiple myeloma treated with melphalan.
Meytes D; Katz DR
Isr J Med Sci; 1973 Aug; 9(8):1044-7. PubMed ID: 4753846
[No Abstract] [Full Text] [Related]
8. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
9. Early changes in bone marrow morphology induced by thalidomide in refractory myeloma patients.
Corso A; Lorenzi A; Zappasodi P; Invernizzi R; Vanelli L; Lazzarino M
Haematologica; 2003 Aug; 88(8):958-60. PubMed ID: 12935985
[No Abstract] [Full Text] [Related]
10. [Dhnmics of histological changes in the bone marrow in a patient with multiple myeloma during the process of treatment with sarcolysin].
Voronin VM; Rybakova ME
Probl Gematol Pereliv Krovi; 1969 Feb; 14(2):53-6. PubMed ID: 5351088
[No Abstract] [Full Text] [Related]
11. Initial bone marrow findings in multiple myeloma. Significance of plasma cell nodules.
Buss DH; Prichard RW; Hartz JW; Cooper MR; Feigin GA
Arch Pathol Lab Med; 1986 Jan; 110(1):30-3. PubMed ID: 3753566
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Cibeira MT; Rozman M; Segarra M; Lozano E; Rosiñol L; Cid MC; Filella X; Bladé J
Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
[TBL] [Abstract][Full Text] [Related]
13. [Erythroleukemia in multiple myeloma. A case report].
Streuli R; Voellmy W
Schweiz Med Wochenschr; 1987 Feb; 117(8):286-91. PubMed ID: 3470922
[TBL] [Abstract][Full Text] [Related]
14. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
15. [Usefulness of a bone marrow immunohistochemical study in multiple myeloma].
Rapazzini P; Bettini R; Rinaldini C; Arrigoni G; Bonato M
Recenti Prog Med; 1988 Jun; 79(6):257-60. PubMed ID: 3047821
[No Abstract] [Full Text] [Related]
16. Non-secretary multiple myeloma in a young Ethiopian: case report.
Teklesilassie H; Sherif A; Diro E
Ethiop Med J; 2010 Apr; 48(2):165-8. PubMed ID: 20608020
[TBL] [Abstract][Full Text] [Related]
17. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
Hideshima T; Mitsiades C; Tonon G; Richardson PG; Anderson KC
Nat Rev Cancer; 2007 Aug; 7(8):585-98. PubMed ID: 17646864
[TBL] [Abstract][Full Text] [Related]
18. Amyloid in bone marrow smears of patients affected by multiple myeloma.
Petruzziello F; Zeppa P; Catalano L; Cozzolino I; Gargiulo G; Musto P; D'Auria F; Liso V; Rizzi R; Caruso N; Califano C; Piro E; Musso M; Bonanno V; Pia Falcone A; Tafuto S; Di Raimondo F; De Laurentiis M; Pane F; Palombini L; Rotoli B
Ann Hematol; 2010 May; 89(5):469-74. PubMed ID: 19894050
[TBL] [Abstract][Full Text] [Related]
19. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide in multiple myeloma.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
